Spirovant Sciences

Spirovant Sciences is a private, clinical-stage biotechnology company pioneering gene therapies for cystic fibrosis and other genetic lung diseases. Its core technology is an integrated AAV + Augmenter platform designed to achieve high, durable expression of therapeutic genes like CFTR in airway cells. The company, led by an experienced team and backed by strategic acquisitions and foundation support, is advancing a lead CF program toward the clinic with the goal of providing a one-time curative treatment.

Proprietary AAV + Augmenter platform consisting of an optimized transgene payload, a novel AAV capsid, and an augmenter component, designed to drive high, durable expression of therapeutic genes in human airway epithelia.

Spirovant competes in the CF space against dominant small molecule therapies (Vertex Pharmaceuticals) and other gene therapy approaches from entities like 4D Molecular Therapeutics, ReCode Therapeutics, and the CF Gene Therapy Consortium. The high bar set by modulator efficacy and the technical difficulty of lung gene delivery create a challenging but potentially high-reward competitive environment.